UPDATE 3-UK Stocks-Factors to watch on Jan 23
Jan 23 Britain's FTSE 100 index is seen opening down 31 points at 7,168 on Monday, according to financial bookmakers, with futures down 0.48 percent ahead of the cash market open.
Jan 4 BioPharmX Corp :
* BioPharmX completes enrollment of BPX-01 Phase 2B OPAL clinical trial for acne vulgaris
* BioPharmX Corp - expect trial results will be available in first half of 2017 Source text for Eikon: Further company coverage:
ZURICH, Jan 23 Actelion's Opsumit drug missed a primary endpoint in a late-stage study of patients with pulmonary arterial hypertension due to Eisenmenger Syndrome, a doctor involved in the trial said in a statement from the Swiss drugmaker.